造影剂肾病的预防研究新进展  

New Progress in Prevention of Contrast Media Nephropathy

作　　者：景世文 陈莎 林玟瑄 杨俊 

机构地区：[1]新疆医科大学研究生学院,新疆 乌鲁木齐 [2]新疆军区总医院神经内科,新疆 乌鲁木齐

出　　处：《临床医学进展》2024年第4期595-600,共6页Advances in Clinical Medicine

摘　　要：血管内介入治疗是目前诊断和治疗脑血管病不可或缺的方式,随着此项技术的不断成熟、发展以及人口老龄化和慢病流行,越来越多的患者接受了这项治疗,但是血管内介入术后引起的造影剂相关性肾病也逐渐增多。造影剂肾病(Contrast-induced nephropathy, CIN)是继肾灌注不足和药物性肾损伤之后发生医院获得性急性肾损伤的三大原因之一。故对于造影剂肾病的认识和预防显得尤为重要,本文就对于造影剂肾病的流行病学、发病机制、预防、生物标记物的研究进展加以综述,为临床医师提供借鉴。Endovascular interventional therapy is currently an indispensable diagnostic and treatment method for the diagnosis and treatment of cardiovascular and cerebrovascular diseases. With the continuous maturity and development of this technology, as well as the aging of the population and the prevalence of chronic diseases, more and more patients require this treatment, but the contrast media-associated kidney disease caused by endovascular interventional surgery is also gradually increasing. Contrast-induced nephropathy (CIN) is one of the three major causes of hospital-acquired acute renal injury following renal hypoperfusion and drug-induced renal injury. Therefore, it is particularly important to understand and prevent contrast induced nephropathy. This article reviews the epidemiology, pathogenesis, prevention and biomarkers of contrast induced nephropathy, so as to provide reference for clinicians.

关 键 词：造影剂肾病 水化疗法 前列地尔 增强体外反搏 肾功能观察指标 

分 类 号：R73[医药卫生—肿瘤]